Now Approved
Indicated to reduce the volume of total new heterotopic ossification (HO) in adults and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP).1
Patient Enrollment FormUnable to submit form
There was an error when submitting your form. Please try again and ensure all required fields are completed.
Try AgainThank you!
Your form has been received. Be on the lookout for a confirmation from Mirum soon.
Visit the Home Page
Mirum Access Plus
Mirum Access Plus (MAP) is a support program with a dedicated team that helps patients, caregivers, and their health care providers access medication and connect with helpful resources.
Learn About Mirum Access PlusReference: 1. ATEBRIOZ™ (zilurgisertib). Prescribing Information. Mirum Pharmaceuticals, Inc. Exclusively licensed from Incyte Corporation.
Proceed to health care professional website
This site contains clinical information intended for US health care professionals.
If you are not a US health care professional, visit the patient site.
INDICATION
ATEBRIOZ is indicated to reduce the volume of total new heterotopic ossification (HO) in adults and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP).
IMPORTANT SAFETY INFORMATION
Contraindications
ATEBRIOZ is contraindicated in pregnancy. ATEBRIOZ can cause fetal harm when administered to a pregnant woman.
Warnings and Precautions
Embryo-Fetal Toxicity: Based on its mechanism of action and findings from animal reproduction studies, ATEBRIOZ can cause fetal harm. Verify that females of reproductive potential are not pregnant prior to initiating treatment. Advise females of reproductive potential to use effective contraception during treatment and for one week after the final dose. Advise patients to discontinue ATEBRIOZ immediately if pregnancy occurs during treatment and to contact their healthcare provider.
Adverse Reactions
The most common adverse reactions (≥10%) are headache, arthralgia, upper respiratory tract infection, epistaxis, and nausea.
Drug Interactions
CYP3A4 Inhibitors: Reduce the ATEBRIOZ dosage to 50 mg orally once daily when used concomitantly with a strong CYP3A4 inhibitor.
CYP3A4 Inducers: Avoid concomitant use of ATEBRIOZ with strong or moderate CYP3A4 inducers.
MATE1 and MATE2-K Substrates: Avoid concomitant use of ATEBRIOZ with MATE1 and MATE2-K substrates (e.g., metformin). If unavoidable, monitor for adverse reactions and consider dose reduction of the substrates if appropriate, according to their approved prescribing information.
Use in Specific Populations
Lactation: Advise patients that breastfeeding is not recommended during treatment with ATEBRIOZ and for at least one week after the final dose.
Dosing Information
The recommended dosage of ATEBRIOZ is 100 mg orally once daily with or without food. ATEBRIOZ tablets may be administered whole or crushed. If crushed, mix 4 tablets (100 mg total) with four tablespoons of water, orange juice, apple sauce, or plain yogurt and administer immediately. Do not store the mixture for future use. Do not administer ATEBRIOZ with grapefruit, pomelo, or juices containing these fruits.
Please see full Prescribing Information, including the Medication Guide, for ATEBRIOZ.
INDICATION
ATEBRIOZ is indicated to reduce the volume of total new heterotopic ossification (HO) in adults and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP).
IMPORTANT SAFETY INFORMATION
Contraindications
ATEBRIOZ is contraindicated in pregnancy. ATEBRIOZ can cause fetal harm when administered to a pregnant woman.
Warnings and Precautions
Embryo-Fetal Toxicity: Based on its mechanism of action and findings from animal reproduction studies, ATEBRIOZ can cause fetal harm. Verify that females of reproductive potential are not pregnant prior to initiating treatment. Advise females of reproductive potential to use effective contraception during treatment and for one week after the final dose. Advise patients to discontinue ATEBRIOZ immediately if pregnancy occurs during treatment and to contact their healthcare provider.
Adverse Reactions
The most common adverse reactions (≥10%) are headache, arthralgia, upper respiratory tract infection, epistaxis, and nausea.
Drug Interactions
CYP3A4 Inhibitors: Reduce the ATEBRIOZ dosage to 50 mg orally once daily when used concomitantly with a strong CYP3A4 inhibitor.
CYP3A4 Inducers: Avoid concomitant use of ATEBRIOZ with strong or moderate CYP3A4 inducers.
MATE1 and MATE2-K Substrates: Avoid concomitant use of ATEBRIOZ with MATE1 and MATE2-K substrates (e.g., metformin). If unavoidable, monitor for adverse reactions and consider dose reduction of the substrates if appropriate, according to their approved prescribing information.
Use in Specific Populations
Lactation: Advise patients that breastfeeding is not recommended during treatment with ATEBRIOZ and for at least one week after the final dose.
Dosing Information
The recommended dosage of ATEBRIOZ is 100 mg orally once daily with or without food. ATEBRIOZ tablets may be administered whole or crushed. If crushed, mix 4 tablets (100 mg total) with four tablespoons of water, orange juice, apple sauce, or plain yogurt and administer immediately. Do not store the mixture for future use. Do not administer ATEBRIOZ with grapefruit, pomelo, or juices containing these fruits.
Please see full Prescribing Information, including the Medication Guide, for ATEBRIOZ.